Limits...
Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.

Watanabe T - Breast Cancer (2013)

Bottom Line: UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil.UFT is characterized by mild adverse events, allowing long-term treatment.The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Hamamatsu Oncology Center, 3-6-13 Chuo, Naka-ku, Hamamatsu, Shizuoka, 430-0929, Japan, twatanab@oncoloplan.com.

ABSTRACT
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, UFT has been most widely used for postoperative chemotherapy in breast cancer. UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil. UFT is characterized by mild adverse events, allowing long-term treatment. The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery. Recently, large clinical trials conducted in Japan have shown that UFT-based postoperative chemotherapy is therapeutically useful in patients with node-negative (n0), high-risk breast cancer. We review the results of clinical trials of postoperative chemotherapy with UFT in Japan and discuss its roles and future prospects.

Show MeSH

Related in: MedlinePlus

Impact of UFT or CMF on QOL in patients taking part in the N·SAS-BC 01 trial. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Breast 23 scores for social functioning (a), nausea and vomiting (b), and upset by hair loss (c). In the graph for social functioning, a higher score indicates better QOL, whereas for nausea and vomiting and upset by hair loss, lower scores indicate better QOL. d FACT-TOI. A higher score indicates better QOL. Data are presented as mean standard error
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3824200&req=5

Fig3: Impact of UFT or CMF on QOL in patients taking part in the N·SAS-BC 01 trial. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Breast 23 scores for social functioning (a), nausea and vomiting (b), and upset by hair loss (c). In the graph for social functioning, a higher score indicates better QOL, whereas for nausea and vomiting and upset by hair loss, lower scores indicate better QOL. d FACT-TOI. A higher score indicates better QOL. Data are presented as mean standard error

Mentions: Oral 5-FU is known to be associated with few adverse events such as gastrointestinal symptoms, myelosuppression, and hair loss. Clinical studies performed to date have shown a similar trend for UFT. The N·SAS-BC01 trial used the European Organization for Research and Treatment of Cancer (EORTC) QLQ C30, QLQ-BR23, and the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires to evaluate patients’ quality of life (QOL). The results of QOL analyses showed that QOL was distinctly better in the UFT group than in the CMF group for about 6 months after the start of treatment. After the completion of CMF therapy, QOL improved, but was similar to that in the UFT group. These findings indicated that a good QOL was maintained during treatment with UFT (Fig. 3).Fig. 3


Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.

Watanabe T - Breast Cancer (2013)

Impact of UFT or CMF on QOL in patients taking part in the N·SAS-BC 01 trial. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Breast 23 scores for social functioning (a), nausea and vomiting (b), and upset by hair loss (c). In the graph for social functioning, a higher score indicates better QOL, whereas for nausea and vomiting and upset by hair loss, lower scores indicate better QOL. d FACT-TOI. A higher score indicates better QOL. Data are presented as mean standard error
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3824200&req=5

Fig3: Impact of UFT or CMF on QOL in patients taking part in the N·SAS-BC 01 trial. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Breast 23 scores for social functioning (a), nausea and vomiting (b), and upset by hair loss (c). In the graph for social functioning, a higher score indicates better QOL, whereas for nausea and vomiting and upset by hair loss, lower scores indicate better QOL. d FACT-TOI. A higher score indicates better QOL. Data are presented as mean standard error
Mentions: Oral 5-FU is known to be associated with few adverse events such as gastrointestinal symptoms, myelosuppression, and hair loss. Clinical studies performed to date have shown a similar trend for UFT. The N·SAS-BC01 trial used the European Organization for Research and Treatment of Cancer (EORTC) QLQ C30, QLQ-BR23, and the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires to evaluate patients’ quality of life (QOL). The results of QOL analyses showed that QOL was distinctly better in the UFT group than in the CMF group for about 6 months after the start of treatment. After the completion of CMF therapy, QOL improved, but was similar to that in the UFT group. These findings indicated that a good QOL was maintained during treatment with UFT (Fig. 3).Fig. 3

Bottom Line: UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil.UFT is characterized by mild adverse events, allowing long-term treatment.The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Hamamatsu Oncology Center, 3-6-13 Chuo, Naka-ku, Hamamatsu, Shizuoka, 430-0929, Japan, twatanab@oncoloplan.com.

ABSTRACT
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, UFT has been most widely used for postoperative chemotherapy in breast cancer. UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil. UFT is characterized by mild adverse events, allowing long-term treatment. The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery. Recently, large clinical trials conducted in Japan have shown that UFT-based postoperative chemotherapy is therapeutically useful in patients with node-negative (n0), high-risk breast cancer. We review the results of clinical trials of postoperative chemotherapy with UFT in Japan and discuss its roles and future prospects.

Show MeSH
Related in: MedlinePlus